Global Glycosylated Peptide Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Peptide glycosylation is a covalent modification that can potentially improve the physicochemical properties of peptides.

Scope of the Report:
Some advantages of glycosylated peptides include: (1) increased bioavailability, (2) increased metabolic stability, (2) targeting specific tissues and organs, (3) reduction in clearance rates, (4) enhanced receptor binding, (5) facilitation of active transport across cell membranes (glucose transporters), and (6) maintaining the overall physical properties of peptides (precipitation, aggregation, thermal and kinetic denaturation).
Glycopeptides are recognized as peptides that contain glycans (carbohydrate molecules) and can be generalized classified into three types based on the linkage or bond type between the amino acid and the glycan: (1) C-linked, (2) O-linked, and (3) N-linked.
The most common type in eukaryotic cells is N-linked glycopeptides, noted by the C-N bond from the side chain of asparagine (Asn/N) amino acid. O-Type glycopeptides are named after the C-O bond from the side chains of serine (Ser) and threonine (Thr) amino acids. The least common C-linked types are recognized as the bond between a tryptophan residue and the sugar mannose.
The worldwide market for Glycosylated Peptide is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
This report focuses on the Glycosylated Peptide in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
Sandoz International
Pfizer
Roche
Teva Pharmaceuticals Industries
Celltrion
Biocon
Dr.Reddys Laboratories
Medtronic
Cipla
Bachem Americas

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Monoclonal Antibodies (MABs)
Erythropoietin (EPO)
Others

Market Segment by Applications, can be divided into
Oncology
Blood Disorder
Others

There are 15 Chapters to deeply display the global Glycosylated Peptide market.
Chapter 1, to describe Glycosylated Peptide Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Glycosylated Peptide, with sales, revenue, and price of Glycosylated Peptide, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Glycosylated Peptide, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Glycosylated Peptide market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Glycosylated Peptide sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions